| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153) | M.D. Anderson Cancer Center | 2022-02-14 |
| Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction (NCT04840264) | Sixth Affiliated Hospital, Sun Yat-sen University | 2022-01-07 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (NCT04535401) | National Cancer Institute (NCI) | 2021-08-13 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (NCT04660760) | Academic and Community Cancer Research United | 2021-06-16 |
| Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca (NCT04921904) | Baylor Research Institute | 2021-06-11 |
| Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer (NCT04511039) | Roswell Park Cancer Institute | 2021-06-08 |
| Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer (NCT04781686) | Zhou Fuxiang | 2021-05-14 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers (NCT04460937) | National Cancer Institute (NCI) | 2021-04-09 |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (NCT03641313) | National Cancer Institute (NCI) | 2020-11-16 |
| Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers (NCT04221893) | University of California, San Francisco | 2020-08-07 |
| MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (NCT03739801) | University of Southern California | 2020-04-06 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer (NCT04220827) | M.D. Anderson Cancer Center | 2019-12-06 |
| IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer (NCT03918499) | City of Hope Medical Center | 2019-04-19 |
| Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (NCT03337087) | Academic and Community Cancer Research United | 2018-11-02 |
| Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma (NCT03395847) | M.D. Anderson Cancer Center | 2018-02-09 |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery (NCT03008278) | National Cancer Institute (NCI) | 2018-02-06 |
| MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C (NCT02391038) | Millennium Pharmaceuticals, Inc. | 2014-12-01 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (NCT01142388) | National Cancer Institute (NCI) | 2010-09-21 |